B7.1-AML vaccine

The B7.1-AML vaccine is an experimental cellular immunotherapy developed for the treatment of acute myeloid leukemia (AML). It consists of leukemic cells that have been genetically engineered, typically via retroviral transduction, to express the costimulatory molecule CD80 (also known as B7.1). The rationale behind this approach is that AML cells often lack the necessary costimulatory signals required to activate T cells, leading to immune ignorance or anergy. By expressing B7.1, the vaccine provides the 'second signal' (binding to CD28 on T cells) alongside tumor-associated antigens, thereby promoting the activation and expansion of leukemia-specific CD8+ cytotoxic T lymphocytes (CTLs). Preclinical studies have demonstrated that while the B7.1-AML vaccine can induce protective immunity and cure mice with a low tumor burden, its efficacy is often surpassed by vaccines incorporating cytokines such as GM-CSF in more advanced stages of the disease.

Other names

B7-1 AML vaccineB-7-1 AML vaccineB 7-1 AML vaccineCD80-AML vaccineCD-80-AML vaccineCD 80-AML vaccineCD80-modified AML vaccineCD-80-modified AML vaccineCD 80-modified AML vaccine